Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6465295 | 0.88 | AR (0.84) | ARRXRARXRBRXRGPGR | |
| SCHEMBL6469615 | 0.88 | AR (0.84) | ARRXRARXRBRXRGPGR | |
| SCHEMBL6469617 | 0.87 | AR (1.00) | ARRXRARXRBRXRGPGR | |
| SCHEMBL6469624 | 0.86 | AR (0.81) | ARRXRARXRBRXRGPGR | |
| SCHEMBL6468888 | 0.83 | AR (0.73) | ARKMT2A | |
| SCHEMBL6467875 | 0.79 | AR (0.69) | ARRXRARXRBRXRGNSD2 | |
| SCHEMBL6468078 | 0.77 | AR (0.66) | ARKMT2A | |
| SCHEMBL3081289 | 0.76 | AR (0.54) | ARRXRARXRBRXRGNSD2 | |
| SCHEMBL6465913 | 0.76 | AR (0.76) | ARNSD2PGR | |
| SCHEMBL6465994 | 0.75 | AR (0.79) | ARNSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1466902-A1 | ANDROGEN RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | SHBG, PRLHR, FSHR | AR 6/4885KMT2A 2015/4885RXRA 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.